CSL

The stats that trace Paul Perreault’s ten-year helmsmanship of CSL Limited would be the envy of any business leader. Share price rose almost six-fold, market capitalization ballooned, investment in research and development tripled, largely driven by the introduction of groundbreaking products, including the first gene therapy for hemophilia B, next-generation influenza vaccines, and life-changing recombinant therapies. The 2022 acquisition of what is now CSL Vifor opens up an exciting new pipeline of therapies for iron deficiency and renal disease.

But the story of Paul’s success cannot be quantified with numbers alone. His legacy stems from his deep commitment to the patients who rely on CSL’s life-saving products. As CEO, Paul saw himself as CSL’s “chief patient officer.” He fervently believed that if the company focused on patients’ needs, business success would follow. And he was right.